MIXED PHENOTYPE ACUTE LEUKEMIA
Clinical trials for MIXED PHENOTYPE ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new MIXED PHENOTYPE ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for MIXED PHENOTYPE ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to stop leukemia relapse after transplant
Disease control OngoingThis study tests whether two drugs, venetoclax and azacitidine, can help prevent leukemia from returning in 100 adults who have already had a stem cell transplant. Participants have high-risk acute myeloid leukemia or related blood cancers and are in remission after transplant. T…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:39 UTC
-
New hope for Hard-to-Treat leukemia: first human trial of ziftomenib launches
Disease control OngoingThis early-stage trial tests a new drug called ziftomenib (KO-539) in people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or control the cancer…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 26, 2026 07:39 UTC
-
New stem cell transplant approach offers hope for blood cancer patients
Disease control OngoingThis study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to lower the risk of graft-versus-host disease, a common complication. The goal is to see i…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated May 26, 2026 07:37 UTC
-
New drug combo targets tough leukemia in early trial
Disease control OngoingThis early-phase study tests a new targeted therapy called PVEK, which delivers chemotherapy directly to cancer cells, combined with a standard chemo regimen (FLAG-Ida) for adults with newly diagnosed high-risk acute myeloid leukemia (AML) and other aggressive blood cancers. The …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:35 UTC
-
New stem cell therapy aims to tame transplant complications in blood cancer patients
Disease control OngoingThis study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. Orca-T is a special stem cell transplant designed to reduce serious side effects like graft-versus-host disease. The trial compares Orca-T to standard stem cell transplants in 187…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated May 26, 2026 07:33 UTC
-
Which donor is best? major trial aims to improve stem cell transplants for kids with blood cancer
Disease control OngoingThis study compares two types of stem cell donors for children, teens, and young adults with high-risk leukemia or myelodysplastic syndrome (MDS). Participants receive a stem cell transplant from either a partially matched family donor or a fully matched unrelated donor. The goal…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 07:32 UTC
-
New drug cocktail shows promise against rare leukemia
Disease control OngoingThis early-stage trial tests a combination of the oral drug venetoclax with standard chemotherapy and targeted therapies in adults with a specific, hard-to-treat leukemia (Ph+ ALL) that is either newly diagnosed or has returned. The main goal is to find the safest dose and see ho…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 26, 2026 07:25 UTC
-
Engineered donor cells aim to improve stem cell transplants for kids with leukemia
Disease control TerminatedThis study tests a specially engineered donor graft (Orca-Q) in children and young adults with certain blood cancers who need a stem cell transplant. The goal is to see if this processed graft is safe and helps the new cells take hold. About 40 participants will be enrolled.
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Liver shield: nutrient may prevent chemo side effects in young leukemia patients
Disease control OngoingThis study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. Liver toxicity from the chemo drug asparaginase often delays treatment, especially in cert…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New combo therapy aims to tame tough childhood leukemia with fewer side effects
Disease control OngoingThis study tests a targeted cancer drug (imatinib) with two different chemotherapy plans in children and teens newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if a milder chemo regimen works just as well as a strong…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Last-Chance cell therapy for blood cancer patients when standard product fails
Disease control TEMPORARILY_NOT_AVAILABLEThis program gives patients with blood cancers like leukemia or myelodysplastic syndrome access to Orca-T, a cell therapy, when the commercial version made for them doesn't meet quality standards. The goal is to provide treatment when no other option is available. Participants ar…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Childhood leukemia maintenance drug trial pulled before starting
Disease control TerminatedThis study was designed to test the safety and best dose of a drug called revumenib in children with certain types of leukemia after they had a stem cell transplant. The goal was to see if revumenib could help prevent the cancer from returning. However, the trial was withdrawn be…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 18, 2026 12:01 UTC